Den 6:e november kommenterade Analysguiden iZafes rapport för det tredje kvartalet.
Following the end of Q3-24, Pharma Equity Group (“PEG” or “the Company”) secured additional funding ...
Redeye comments on Active Biotech's 2024 rights issue and updates its base case.
Refine Group AB (”Refine”, ”Koncernen” eller ”Bolaget”) är en varumärkesgrupp med ett digitalt fokus...
Underliggande verksamheter går fortsatt mycket bra, men viss mixförskjutning och förberedelsekostnad...
Redeye comments on Embracer's announcment of Asmodee's financial targets and an equity investment of...
Redeye downgrades Nekkar’s outlook on the back of a Q3’24 report that missed our forecast, mainly dr...
Lumi Gruppen continues to see high demand for its ONH courses, reporting a 20% y/y revenue increase ...
Redeye provides a brief comment on today’s news that Flexion Mobile has filed its 2023 annual accoun...
Redeye return with a research update following BioArctic's Q3 report and recent events, including th...
Redeye provides a research update following the Q3 report published by OncoZenge earlier today.
Redeye has revised its estimates after Starbreeze's Q3 report.
Redeye updates on Better Collective post Q3-results, where we have made limited changes to our estim...
Nettoomsättningen för det tredje kvartalet uppgick till 9,7 MEURO (10,3), vilket motsvarade en minsk...
Redeye updates its estimates following CTEK’s Q3 report, which was better than we expected.
Redeye states BeammWave’s report was insignificant, and the customer announced the morning after was...
Redeye updates its estimates and valuation following Navigo releasing its Q3 2024 report.
Solid Q3, with more sequential improvements '24e-'26e sales down 5-6% on slightly softer orders than...
Minor Q3 miss but strong YTD performance Strong balance sheet, ready to act on opportunities Fair va...
24% organic sales growth y-o-y Improved gross margin due to price adjustments Opex growth to abate i...